TB-500 vs GHK-Cu
Side-by-Side Comparison
| Attribute | Tb 500 | Ghk Cu |
|---|---|---|
| Category | Healing & Recovery | Skin & Tissue Repair |
| Mechanism | TB-500 works primarily through actin sequestration — it binds to G-actin monomers, preventing premature polymerization, which allows repair cells to migrate rapidly to injured areas. | GHK-Cu chelates copper(II) ions via its histidine residue and delivers bioavailable copper directly to cells, preventing free copper oxidative damage. |
| Evidence Rating | D — Preclinical | F — No Regulatory Activity |
| Clinical Status | Research-only / Veterinary use in some jurisdictions. Limited human RCTs completed. | Available in cosmetic formulations; no drug approval |
| Safety Profile | A safety-focused RCT in 40 healthy adults (2010) was designed expressly to assess safety and found minimal adverse effects with synthetic thymosin-beta 4; No significant safety concerns in published human studies to date; TB-500 administration has produced minimal side effects in animal and human studies alike | Safety profile is excellent with minimal side effects reported in decades of cosmetic use and clinical research (PMID: 29986520); Topical forms are generally well-tolerated; mild skin irritation rare and typically limited to very sensitive skin |
| Route | Subcutaneous | Subcutaneous, Topical (cream/serum), or Intradermal (microneedling) |
| Dose Range | 500–1000 mcg/day SC (~5 mg/week average) | SC: 50–200 mcg/day; Topical: 1–4% cream or serum applied to target area |
| Frequency | Once daily | SC: Once daily; Topical: 1–2x daily |
| Molecular Weight | ~889 g/mol | ~403.9 g/mol |
| Half-Life | <2 hours plasma half-life; tissue effects persist 2–3 days | ~30 minutes plasma |
Overview
TB-500 and GHK-Cu are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
TB-500 — Mechanism & Evidence
TB-500 is a synthetic fragment of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide found throughout human tissues. TB-500 contains the active healing region (sequence: Ac-LKKTETQ, MW ~889 g/mol) responsible for cell migration and tissue repair. It has a handful of human RCTs for wound healing and dry eye, plus a dedicated safety trial in 40 healthy adults showing minimal adverse effects. Despite this, it remains unapproved for human therapeutic use in all major markets and is banned by WADA and in horse racing.
Key claims: Accelerates wound healing; Reduces inflammation; Promotes cardiac repair.
GHK-Cu — Mechanism & Evidence
GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, saliva, and urine. First discovered by Dr. Loren Pickart in 1973, plasma levels average 200 ng/mL at age 20 but decline to ~80 ng/mL by age 60. It has been extensively studied for wound healing, collagen synthesis, skin regeneration, and gene modulation, with decades of cosmetic use and a broad safety profile. Molecular weight is approximately 340 g/mol (as the copper complex), with the formula C14H24N6O4Cu.
Key claims: Improves skin firmness and elasticity; Promotes wound healing; Reduces fine lines and wrinkles.
Shared Research Applications
These peptides target different research areas. TB-500 focuses on Injury Recovery, Anti-Inflammatory, while GHK-Cu targets Skin Health, Anti-Aging, Wound Healing.
Safety Considerations
TB-500: A safety-focused RCT in 40 healthy adults (2010) was designed expressly to assess safety and found minimal adverse effects with synthetic thymosin-beta 4 No significant safety concerns in published human studies to date; TB-500 administration has produced minimal side effects in animal and human studies alike Common anecdotal side effects: injection site pain/redness, lightheadedness, mild headache, nausea, fatigue
GHK-Cu: Safety profile is excellent with minimal side effects reported in decades of cosmetic use and clinical research (PMID: 29986520) Topical forms are generally well-tolerated; mild skin irritation rare and typically limited to very sensitive skin Injectable forms: mild injection site reactions, lightheadedness, nausea, flu-like symptoms possible; rotate injection sites to reduce local irritation
Related Products
Related Research News
TB-500: Thymosin Beta-4's Role in Healing and Repair
TB-500, known as thymosin β4, is a 43-amino-acid peptide first isolated from calf thymus in 1966 by Goldstein et al. It regulates actin in the body, supporting processes like wound healing, angiogenesis, and inflammation control. Research highlights its potential in treating conditions such as myocardial infarction, corneal injuries, and lung damage.
BPC-157 + TB-500 Peptide Blend: Research on Healing and Repair
The BPC-157 and TB-500 peptide blend draws attention in research for potential synergy in tissue repair, angiogenesis, and reducing inflammation. BPC-157, a 15-amino-acid synthetic peptide, interacts with growth factors in preclinical models. TB-500, a 43-amino-acid analog of Thymosin Beta-4, supports cell migration and regeneration. Studies explore their roles in wound healing, tendon recovery, and more.
GHK-Cu: Copper Peptide in Tissue Repair and Skin Research
GHK-Cu, or glycyl-L-histidyl-L-lysine copper complex, stands out as a naturally occurring peptide central to human tissue maintenance and repair. Found in plasma, saliva, urine, and skin, its levels drop from about 200 ng/mL in young adults with age, linking to reduced regeneration. Preclinical studies highlight its roles in collagen production, wound healing, angiogenesis, anti-inflammation, and more, with the copper complex showing greater potency than unbound GHK.